张锋岂

[摘要] 目的 分析吲哚布芬联合波立维在HR-nice（高危非致残性脑血管病）治疗中的疗效与安全性。方法 方便选取2017年3月—2018年10月该院收治的HR-nice患者72例为研究对象，随机摸球法分为对照组36例，主要为吲哚布芬单独治疗，观察组36例采用吲哚布芬联合波立维治疗，对比两种治疗方式的效果。结果 两组患者治疗前APTT（活化部分凝血活酶时间）、FIB（纤维蛋白原）患者血液指标，差异无统计学意义（P>0.05）;观察组患者FIB低于对照组，APTT和PT（凝血酶原时间）指标显著高于对照组，差异有统计学意义（P<0.05）;两组患者不良反应率无明显差异，差异无统计学意义（χ2=0.214，P>0.05）;治疗后1、7 d观察组患者神经功能评分分别为（12.69±2.19）分、（7.28±1.39）分显著低于对照组，差异有统计学意义（t=3.511、6.161，P<0.05）。结论 HR-nice患者采用吲哚布芬联合波立维治疗时可有效提升治疗效果以及安全性，有临床应用价值。

[关键词] 吲哚布芬;波立维;在HR-nice;血液学指标

[Abstract] Objective To analyze the efficacy and safety of indobufen combined with bolibive in the treatment of HR-nice （high-risk non-disabling cerebrovascular disease）. Methods A total of 72 HR-nice patients who were treated the hospital from March 2017 to October 2018 were convenient selected as the research objects. The random touch method was divided into 36 cases in the control group， which were mainly treated with indobufen alone， and 36 patients in the observation group were treated with Indobufen combined with bolivive therapy， comparing the effects of the two treatments. Results There were no significant differences in blood indexes between APTT （activated partial thromboplastin time） and FIB （fibrinogen） patients before treatment in the two groups， and there was no statistical significance （P>0.05）. The FIB in the observation group was lower than that in the control group. APTT and PT （prothrombin time） were significantly higher than those in the control group， which was statistically significant（P<0.05）; there was no significant difference in the adverse reaction rate between the two groups of patients， and the difference was not statistically significant（χ2=0.214， P>0.05） ; The neurological scores of the observation group at 1 d and 7 d after treatment were （12.69±2.19） points and （7.28±1.39） points， which were significantly lower than those of the control group， and the differences were statistically significant（t=3.511， 6.161， P<0.05）. Conclusion HR-nice patients can effectively improve the treatment effect and safety when they are treated with indobufen combined with bolivive， which has clinical application value.

[Key words] Indobufen; Polivir; in HR-nice; Hematology index

腦血管疾病为严重威胁我国人民群众生命健康的重要疾病，有致残率以及死亡率高的特点，同时也有较高复发率，严重影响正常生活。HR-nice（高危非致残性脑血管病）为脑血管疾病严重类型，同时也为重要防控人群。现阶段对此种疾病多为溶栓治疗，早期治疗可有效控制患者脑组织和缺血半暗带，降低神经功能损伤，提升生活质量。有学者[1]提出吲哚布芬、波立维均可有效控制患者神经功能缺失、提升整体治疗效果。现选取2017年3月—2018年10月该院收治的72例患者为研究对象，分析不同治疗方式下患者干预效果，报道如下。

1  资料与方法

1.1  一般资料

方便选取该院收治的72例HR-nice患者，纳入标准：①患者时间24 h之内患者;②急性多发性脑梗死患者;③严重大动脉粥样硬化患者;④所有患者均签署知情同意书，并通过医院伦理委员会的批准;排除标准：①心源性栓塞患者;②进行抗凝治疗患者;③有胃肠道出血史患者。对照……